711 related articles for article (PubMed ID: 7627978)
1. Identification and characterization of an Epstein-Barr virus-specific T-cell response in the pathologic tissue of a patient with Hodgkin's disease.
Dolcetti R; Frisan T; Sjöberg J; De Campos-Lima PO; Pisa P; De Re V; Gloghini A; Rizzo S; Masucci MG; Boiocchi M
Cancer Res; 1995 Aug; 55(16):3675-81. PubMed ID: 7627978
[TBL] [Abstract][Full Text] [Related]
2. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M
Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783
[TBL] [Abstract][Full Text] [Related]
3. T cell recognition of Epstein-Barr virus associated lymphomas.
Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
[TBL] [Abstract][Full Text] [Related]
4. Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.
Chapman AL; Rickinson AB; Thomas WA; Jarrett RF; Crocker J; Lee SP
Cancer Res; 2001 Aug; 61(16):6219-26. PubMed ID: 11507075
[TBL] [Abstract][Full Text] [Related]
5. Recognition of Epstein-Barr virus-associated gastric carcinoma cells by cytotoxic T lymphocytes induced in vitro with autologous lymphoblastoid cell line and LMP2-derived, HLA-A24-restricted 9-mer peptide.
Okugawa K; Itoh T; Kawashima I; Takesako K; Mazda O; Nukaya I; Yano Y; Yamamoto Y; Yamagishi H; Ueda Y
Oncol Rep; 2004 Oct; 12(4):725-31. PubMed ID: 15375491
[TBL] [Abstract][Full Text] [Related]
6. Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis.
Strang G; Rickinson AB
Eur J Immunol; 1987 Jul; 17(7):1007-13. PubMed ID: 2440688
[TBL] [Abstract][Full Text] [Related]
7. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens.
Masucci G; Mellstedt H; Masucci MG; Szigeti R; Ernberg I; Björkholm M; Tsukuda K; Henle G; Henle W; Pearson G
Cancer Res; 1984 Mar; 44(3):1288-300. PubMed ID: 6318984
[TBL] [Abstract][Full Text] [Related]
8. Analysis of cellular immune response to EBV by using cloned T cell lines.
Slovin SF; Schooley RT; Thorley-Lawson DA
J Immunol; 1983 May; 130(5):2127-32. PubMed ID: 6187840
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the growth of Epstein-Barr virus-infected B cells. I. Growth regression by E rosetting cells from VCA-positive donors is a combined effect of autologous mixed leukocyte reaction and activation of T8+ memory cells.
Konttinen YT; Bluestein HG; Zvaifler NJ
J Immunol; 1985 Apr; 134(4):2287-93. PubMed ID: 2857749
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of allogeneic restriction of human cytotoxic T cell clones specific for Epstein Barr virus.
Tanaka Y; Sugamura K; Hinuma Y
J Immunol; 1982 Mar; 128(3):1241-5. PubMed ID: 6173428
[TBL] [Abstract][Full Text] [Related]
11. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. III. Establishment of HLA-restricted cytotoxic T cell lines using interleukin 2.
Wallace LE; Rowe M; Gaston JS; Rickinson AB; Epstein MA
Eur J Immunol; 1982 Dec; 12(12):1012-8. PubMed ID: 6297919
[TBL] [Abstract][Full Text] [Related]
13. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
Ulaeto D; Wallace L; Morgan A; Morein B; Rickinson AB
Eur J Immunol; 1988 Nov; 18(11):1689-97. PubMed ID: 2904885
[TBL] [Abstract][Full Text] [Related]
14. Establishment and characterization of Epstein-Barr virus-specific human CD4+ T lymphocyte clones.
Honda S; Takasaki T; Okuno K; Yasutomi M; Kurane I
Acta Virol; 1998 Nov; 42(5):307-13. PubMed ID: 10358731
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
16. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
Callahan J; Pai S; Cotter M; Robertson ES
Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
[TBL] [Abstract][Full Text] [Related]
17. Expression of HLA-A2 antigen in human melanoma cell lines and its role in T-cell recognition.
Pandolfi F; Boyle LA; Trentin L; Kurnick JT; Isselbacher KJ; Gattoni-Celli S
Cancer Res; 1991 Jun; 51(12):3164-70. PubMed ID: 1904004
[TBL] [Abstract][Full Text] [Related]
18. Human cytotoxic T lymphocytes. III. Large numbers of peripheral blood T cells clonally develop into allorestricted anti-viral cytotoxic T cell populations in vitro.
Kabelitz D; Herzog WR; Heeg K; Wagner H; Reimann J
J Mol Cell Immunol; 1987; 3(1):49-60. PubMed ID: 2855406
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus (EBV)-induced long-term proliferation of CD4+ lymphocytes leading to T lymphoblastoid cell lines carrying EBV.
Guan M; Romano G; Henderson EE
Anticancer Res; 1999; 19(4B):3007-17. PubMed ID: 10652585
[TBL] [Abstract][Full Text] [Related]
20. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]